


Manager PR & Communications Jan Phillip Denkers

Evotec SE reports results for the first quarter 2021
Evotec SE today announced the financial results and corporate updates for the first quarter 2021. ...
Read more …
Evotec SE: fiscal year 2020 results
Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2020. ...
Read more …
Evotec & Takeda: strategic RNA alliance
Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover ...
Read more …
Evotec & Medical Center Hamburg-Eppendorf Enter Partnership
Evotec SE today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf (“UKE”) for the development of a highly ...
Read more …
Cord Dohrmann Appointed to Council of Science & Humanities
Evotec today announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities (German: “Wissenschaftsrat”) for a term of three ...
Read more …
Development partnership focused on oncology target
Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. ...
Read more …
Just - Evotec produce antibody products against COVID-19
Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to ...
Read more …
Indivumed’s multi-omics database IndivuType
More than 200 participants from around the globe, including fourteen of the top 20 pharma companies, numerous biotech companies, and members from leading academic cancer ...
Read more …
Just-Evotec Biologics partners with ABL against HIV
Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a ...
Read more …
Evotec participates in Exscientia's financing round
Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence (“AI”)-driven drug discovery company. The ...
Read more …- 1
- 2